UK competition regulator looking into $39 bln AstraZeneca-Alexion deal
The $39 billion acquisition of the United States based firm Alexion by the British pharma giant AstraZeneca is being reviewed by the competition regulator of the United Kingdom because of its concerns that the company formed by the merger will have a negative impact on completion in the industry in the UK and elsewhere. Comments…









